SBFM
Price
$0.17
Change
-$0.05 (-22.73%)
Updated
Oct 22 closing price
Capitalization
647.52K
21 days until earnings call
Intraday BUY SELL Signals
TLRY
Price
$2.93
Change
+$0.01 (+0.34%)
Updated
Oct 22 closing price
Capitalization
411.44M
Intraday BUY SELL Signals
Interact to see
Advertisement

SBFM vs TLRY

SBFM vs TLRY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SBFM vs. TLRY commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SBFM is a Hold and TLRY is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for SBFM with price predictions
Oct 22, 2026

SBFM sees MACD Histogram crosses below signal line

SBFM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 40 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBFM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SBFM entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

SBFM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.024) is normal, around the industry mean (10.407). P/E Ratio (-0.018) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SBFM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBFM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for TLRY with price predictions
Oct 22, 2026

TLRY in upward trend: price may jump up because it broke its lower Bollinger Band on September 30, 2026

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 35 cases where TLRY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 72 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.255) is normal, around the industry mean (10.407). P/E Ratio (-2.688) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
SBFM vs TLRY: Fundamental Ratings
SBFM
TLRY
OUTLOOK RATING
1..100
9656
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
9889
P/E GROWTH RATING
1..100
9716
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (23) in the Biotechnology industry is in the same range as SBFM (29) in the null industry. This means that TLRY’s stock grew similarly to SBFM’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SBFM (100) in the null industry. This means that TLRY’s stock grew similarly to SBFM’s over the last 12 months.

TLRY's SMR Rating (93) in the Biotechnology industry is in the same range as SBFM (96) in the null industry. This means that TLRY’s stock grew similarly to SBFM’s over the last 12 months.

TLRY's Price Growth Rating (89) in the Biotechnology industry is in the same range as SBFM (98) in the null industry. This means that TLRY’s stock grew similarly to SBFM’s over the last 12 months.

TLRY's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for SBFM (97) in the null industry. This means that TLRY’s stock grew significantly faster than SBFM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SBFMTLRY
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
74%
Stochastic
ODDS (%)
N/A
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
N/A
Bullish Trend 17 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (SBFM: $0.22 vs. TLRY: $2.93)
Brand notoriety: SBFM: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SBFM: 5% vs. TLRY: 167%
Market capitalization -- SBFM: $647.52K vs. TLRY: $411.44M
SBFM [@Pharmaceuticals: Generic] is valued at $647.52K. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $411.44M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SBFM’s FA Score shows that 1 FA rating(s) are green while TLRY’s FA Score has 2 green FA rating(s).

  • SBFM’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 2 green, 3 red.
According to our system of comparison, TLRY is a better buy in the long-term than SBFM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SBFM’s TA Score shows that 2 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • SBFM’s TA Score: 2 bullish, 3 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than SBFM.

Price Growth

SBFM (@Pharmaceuticals: Generic) experienced а -11.36% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -8.72% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.

Reported Earning Dates

SBFM is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.94% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
SBFM
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and SXTC have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and SXTC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-22.47%
SXTC - SBFM
31%
Poorly correlated
-34.25%
OGI - SBFM
28%
Poorly correlated
-0.43%
CGC - SBFM
24%
Poorly correlated
-1.00%
TLRY - SBFM
24%
Poorly correlated
+0.34%
ELAN - SBFM
23%
Poorly correlated
+0.62%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIFU11.330.48
+4.42%
AIFU Inc
UA4.730.16
+3.50%
Under Armour
SF67.851.44
+2.17%
Stifel Financial Corp
INDI1.68-0.12
-6.67%
indie Semiconductor
BJDX0.63-0.05
-6.94%
Bluejay Diagnostics Inc.